Clinical trial
Rivastigmine For Methamphetamine Dependent Individuals
NCT00158210 · National Institute on Drug Abuse (NIDA), NIH · Completed
Key facts
| NCT number | NCT00158210 |
|---|---|
| Title | Rivastigmine For Methamphetamine Dependent Individuals |
| Official title | Double-Blind Randomized Placebo Controlled Trial of Rivastigmine (Excelon) as a Potential Medication for Methamphetamine Abuse |
| Lead sponsor | National Institute on Drug Abuse (NIDA), NIH |
| Collaborators | University of California, Los Angeles |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Substance-Related Disorders |
| Intervention type | Drug |
| Interventions | Rivastigmine |
| Enrollment | 18 |
| Start date | May 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: